bullish
PharmaEssentia GDS Issuance - Strong Revenue Growth and Narrowing Losses
927 Views13 Apr 2023 19:39
Pharmaessentia Corp (6446 TT) aims to raise around US$412m (TWD12.6bn) via a GDS issuance. In this note, we will talk about the deal dynamics and run the deal through our ECM framework.
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
- Pharmaessentia Corp (6446 TT): Readying for Next Growth Phase with Besremi’s Continued Traction07 Mar 2024
- Pharmaessentia Corp (6446 TT): Besremi Revenue Is Recovering; Fund Raising Through GDS Completed21 Jul 2023
- PharmaEssentia GDS Issuance - Strong Revenue Growth and Narrowing Losses13 Apr 2023
x